Medicine and Dentistry
Diabetic Macular Edema
100%
Maturity Onset Diabetes of the Young
100%
Wet Macular Degeneration
100%
Ranibizumab
100%
Primary Health Care
62%
Cataract Surgery
55%
Randomized Controlled Trial
52%
Cognitive Defect
50%
Low Level Laser Therapy
50%
Dark Adaptation
50%
Specialist Care
50%
Microangiopathy
50%
Controlled Clinical Trial
50%
Caregiver Burden
50%
Patient with Type 2 Diabetes
50%
Nonsteroid Antiinflammatory Agent
50%
Retina Macula Cystoid Edema
50%
Glycemic Control
50%
Case-Control Study
50%
Dexamethasone
50%
Blood Pressure
45%
Visual Acuity
44%
Optical Coherence Tomography
37%
Retinal Blood Vessel
37%
Arm
34%
Diabetes
33%
Kidney Function
33%
Quality of Life
32%
Adverse Event
25%
Client
25%
Pressure Control
16%
Clinical Management
16%
Body Mass Index
16%
General Medicine
16%
Hemoglobin A1c
16%
Metabolic Regulation
16%
Prospective Study
16%
Systolic Blood Pressure
16%
Best Corrected Visual Acuity
15%
Diabetic Retinopathy
15%
Retinopathy
12%
Blood Clotting
12%
Hypoxia
12%
Retina Image
12%
Epiphora
12%
Agents Acting on the Eye
12%
Microvessel
12%
Neuropathy
12%
Growth Factor
12%
Cross Sectional Study
12%
Nursing and Health Professions
Non Insulin Dependent Diabetes Mellitus
50%
Wet Macular Degeneration
50%
Patient with Type 2 Diabetes
50%
Blood Pressure
50%
Specialist Care
50%
Primary Health Care
50%
Ranibizumab
50%
Quality of Life
25%
Client
25%
Visual Acuity
25%
Pressure Control
25%
Systolic Blood Pressure
25%
General Practice
25%
Clinical Management
25%
Hemoglobin A1c
25%
Primary Medical Care
25%
Intraocular Drug Administration
16%
Socialized Medicine
12%
Cross-Sectional Study
12%
Epiphora
12%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetic Retinopathy
87%
Inflammation
50%
Mitochondrial DNA
50%
Dexamethasone
50%
Ranibizumab
50%
Wet Macular Degeneration
50%
Controlled Clinical Trial
50%
Diabetic Macular Edema
50%
Combination Therapy
25%
Cataract
25%
Cross-Sectional Study
17%
Visual Impairment
12%
Macular Edema
12%
Monotherapy
12%
Proliferative Diabetic Retinopathy
9%
Cytokine
9%
